Status:
UNKNOWN
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
Lead Sponsor:
University of Oklahoma
Conditions:
Fallopian Tube Cancer
Fallopian Tube Infection
Eligibility:
FEMALE
18-99 years
Phase:
EARLY_PHASE1
Brief Summary
This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin ...
Detailed Description
Subjects in this study will receive low dose aspirin for 14 days before undergoing surgery to remove fallopian tubes removed to determine whether aspirin decreases inflammation in the fallopian tube. ...
Eligibility Criteria
Inclusion
- Women undergoing gynecologic surgery for presumed benign indications that includes the removal of their fallopian tubes. This may include sterilization procedures, hysterectomy or partial or full adnexectomy.
- Eligible women will have fulfilled their childbearing desires
- Age \> 21 Considered low risk for prevalent fallopian tube cancer (not undergoing risk reducing surgery for a known BRCA mutation or other known hereditary predisposition syndrome, family history of ovarian cancer in a first degree relative.
Exclusion
- Males
- Women who have presumed or known gynecologic cancer
- Women less than 21 years of age
- Women currently on either regular aspirin therapy, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen or chronic steroidal anti-inflammatory medications.
- Women with known bleeding diathesis or bleeding disorder.
- Women who do not consent for removal of both fallopian tubes.
- Women with a history of gastritis or peptic ulcer disease requiring treatment. (Patients with a history of occasional H1 or H2 blocker use for gastro esophageal reflux disease are NOT excluded).
- Women with reported aspirin or NSAID allergy
- Women with asthma and/or nasal polyps
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03771651
Start Date
March 1 2019
End Date
June 1 2025
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73117